Patents Assigned to The Aaron Diamond Aids Research Center
-
Patent number: 10308707Abstract: In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.Type: GrantFiled: December 21, 2017Date of Patent: June 4, 2019Assignee: AARON DIAMOND AIDS RESEARCH CENTERInventors: David D. Ho, Yaoxing Huang, Jian Yu
-
Patent number: 9884905Abstract: In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.Type: GrantFiled: January 25, 2017Date of Patent: February 6, 2018Assignee: AARON DIAMOND AIDS RESEARCH CENTERInventors: David D. Ho, Yaoxing Huang, Jian Yu
-
Patent number: 9587012Abstract: In various embodiments, the present invention relates generally to using bispecific antibodies in the prevention and treatment of HIV.Type: GrantFiled: December 2, 2014Date of Patent: March 7, 2017Assignee: AARON DIAMOND AIDS RESEARCH CENTERInventors: David D. Ho, Yaoxing Huang, Jian Yu
-
Patent number: 8883745Abstract: The invention is directed to novel synthetic C-glycolipids that selectively induce a ThI-type immune response characterized by enhanced IL-12 secretion and increased activation of dendritic cells. The compounds of the invention are thereby useful in treating infections, cancers, cell proliferative disorders, and autoimmune diseases, both directly and as adjuvants.Type: GrantFiled: May 22, 2007Date of Patent: November 11, 2014Assignees: New York University, The Aaron Diamond Aids Research Center For The City Of New York, Research Foundation Of The City University Of New YorkInventors: Moriya Tsuji, Guangwu Chen, Richard W. Franck, Guangli Yang
-
Publication number: 20100233207Abstract: The invention is directed to novel synthetic C-glycolipids that selectively induce a ThI-type immune response characterized by enhanced IL-12 secretion and increased activation of dendritic cells. The compounds of the invention are thereby useful in treating infections, cancers, cell proliferative disorders, and autoimmune diseases, both directly and as adjuvants.Type: ApplicationFiled: May 22, 2007Publication date: September 16, 2010Applicants: New York University, Research Foundation of the City University of New York, The Aaron Diamond AIDS Research Center for the City of New York, Inc.Inventors: Moriya Tsuji, Guangwu Chen, Richard W. Franck, Guangli Yang
-
Patent number: 7771726Abstract: The present invention relates to methods and compositions for augmenting an immunogenicity of an antigen in a mammal, comprising administering said antigen together with an adjuvant composition that includes a synthetic glycolipid compound of Formula I, as described herein. According to the present invention, the use of a compound of Formula I as an adjuvant is attributed at least in part to the enhancement and/or extension of antigen-specific Th1-type responses, in particular, CD8+ T cell responses. The methods and compositions of the present invention can be useful for prophylaxis and treatment of various infectious and neoplastic diseases.Type: GrantFiled: October 8, 2004Date of Patent: August 10, 2010Assignees: New York University, The Research Foundation of the City University of New York, Aaron Diamond Aids Research CenterInventors: Moriya Tsuji, John Schmieg, Richard Franck, Yaoxing Huang
-
Patent number: 7320878Abstract: The present invention concerns a further development and use of biological assays to determine the amount or concentration of an active ingredient present in a sample. The enzyme assay of the present invention determines the amount or concentration of protease inhibitors, including retroviral protease inhibitors such as HIV inhibitors.Type: GrantFiled: November 8, 2002Date of Patent: January 22, 2008Assignees: Tibotec Pharmaceuticals, Ltd., Aaron Diamond Aids Research Center, The Rockefeller UniversityInventors: Sergei Gulnik, Betty Yu, John W Erickson, Martin Markowitz
-
Publication number: 20040096820Abstract: The invention identifies polypeptide biomarkers of disease progression or nonprogression by comparative protein profiling of samples from progressors and nonprogressors subpopulations of a population exposed to the pathogen or sharing a risk facto causing the disease. The polypeptides, their ligands, and modulators find use as diagnostic, prognostic, and therapeutic agents.Type: ApplicationFiled: May 30, 2003Publication date: May 20, 2004Applicants: Ciphergen Biosystems, Inc., Aaron Diamond AIDS Research Center, The Rockefeller UniversityInventors: William E. Rich, David D. Ho, Linqi Zhang
-
Publication number: 20040091498Abstract: The present invention relates to inhibition of viruses, e.g., HIV, using defensins. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, nucleic acids, antisense nucleic acids, and ribozymes, that increase naturally occurring defensin expression or activity, thereby inhibiting HIV in a cell; as well as to the use of expression profiles and compositions in diagnosis and prophylaxis, and therapy related to HIV infection and related disease states such as AIDS.Type: ApplicationFiled: May 30, 2003Publication date: May 13, 2004Applicants: Aaron Diamond AIDS Research Center, The Rockefeller University, Ciphergen Biosystems, Inc.Inventors: Linqi Zhang, David D. Ho, Rebecca E. Caffrey, Enrique A. Dalmasso, Jianfeng Mei
-
Publication number: 20030052839Abstract: This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.Type: ApplicationFiled: December 21, 2001Publication date: March 20, 2003Applicant: Progenics Pharmaceuticals, Inc., Aaron Diamonds AIDS Research Center (ADARC)Inventors: James M. Binley, Norbert Schuelke, William C. Olson, Paul J. Maddon, John P. Moore
-
Patent number: 6258527Abstract: Entry of HIV-1 into target cells requires cell surface CD4 as well as additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T cell lines was recently identified and named fusin. Fusin, however, does not promote entry of macrophage-tropic viruses that are believed to be the key pathogenic strains in vivo. It has now been determined that the principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR5, a receptor for the &bgr;-chemokines RANTES, MIP-1&agr;, and MIP-1&bgr;.Type: GrantFiled: May 21, 1997Date of Patent: July 10, 2001Assignees: The Aaron Diamond Aids Research Center, New York UniversityInventors: Dan R. Littman, Hongkui Deng, Wilfried Ellmeier, Nathaniel R. Landau, Rong Liu
-
Patent number: 6057102Abstract: Entry of HIV-1 into target cells requires cell surface CD4 as well as additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T cell lines was recently identified and named fusin. Fusin, however, does not promote entry of macrophage-tropic viruses that are believed to be the key pathogenic strains in vivo. It has now been determined that the principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR5, a receptor for the .beta.-chemokines RANTES, MIP-1.alpha., and MIP-1.beta.. It has also been found that individuals who are homozygous for a mutation of the CKR-5 receptor are resistent to HIV infection; in vitro infection requires a 1000-fold higher dose of HIV than normal cells. The mutation results in complete suppression of CKR-5 expression.Type: GrantFiled: August 8, 1997Date of Patent: May 2, 2000Assignee: The Aaron Diamond Aids Research CenterInventors: Nathaniel R. Landau, Richard A. Koup, Rong Liu, William Paxton
-
Patent number: 5939320Abstract: Entry of HIV-1 into target cells requires cell surface CD4 as well as additional host cell cofactors. A cofactor required for infection with virus adapted for growth in transformed T cell lines was recently identified and named fusin. Fusin, however, does not promote entry of macrophage-tropic viruses that are believed to be the key pathogenic strains in vivo. It has now been determined that the principal cofactor for entry mediated by the envelope glycoproteins of primary macrophage-tropic strains of HIV-1 is CC-CKR5, a receptor for the .beta.-chemokines RANTES, MIP-1.alpha., and MIP-1.beta..Type: GrantFiled: June 19, 1996Date of Patent: August 17, 1999Assignees: New York University, The Aaron Diamond Aids Research CenterInventors: Dan R. Littman, Hongkui Deng, Wilfried Ellmeier, Nathaniel R. Landau, Rong Liu